Skip to main content
GERN
NASDAQ Life Sciences

Geron Swings to Profit as RYTELO Revenue Hits $60.1M, Opex Guidance Cut

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.958
Mkt Cap
$597.5M
52W Low
$0.84
52W High
$2.01
52W Position info
14% above low
Off High info
52% below high
Rel. Volume info
5.0× avg
Market data snapshot near publication time

GERN is trading near its 52-week low of $0.84 (14% above the low) on elevated volume (5.0× avg).

Summary

RYTELO net product revenue came in at $60.2 million for Q3 2026, up 5% from Q2 and well above the $47.2 million booked a year earlier, with demand up 10% sequentially and ordering accounts up roughly 8% to about 1,700. The company posted net income of $1.4 million versus a $18.4 million loss a year ago, driven by the higher revenue and total operating expenses falling to $54.4 million from $61.1 million. Management reiterated full-year RYTELO revenue at the mid-to-high end of $220 million to $240 million and cut the 2026 opex range to $220 million to $230 million from $230 million to $240 million. Cash and marketable securities stood at $339.4 million at quarter end, up from $326.9 million on June 30. The release also recaps the October 28 discontinuation of the Phase 3 IMpactMF myelofibrosis trial, which leaves the story almost entirely dependent on RYTELO in lower-risk MDS; the new piece is the gated European launch, with Germany expected by year-end and France in 2027.

At the time of this announcement, GERN was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $597.5M. The 52-week trading range was $0.84 to $2.01. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GERN - Latest Insights

GERN
Nov 04, 2026, 5:11 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.985 info
Change: -$0.085 (-8%) info
Market Cap: $638.376M info
GERN
Nov 04, 2026, 7:12 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.970
Real-time Price: $0.985 info
Change: +$0.015 (+2%) info
Market Cap: $638.376M info
GERN
Oct 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.15
Real-time Price: $0.985 info
Change: -$0.1648 (-14%) info
Market Cap: $638.376M info
GERN
Aug 05, 2026, 4:41 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $0.985 info
Change: -$0.615 (-38%) info
Market Cap: $638.376M info
GERN
May 21, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.25
Real-time Price: $0.985 info
Change: -$0.265 (-21%) info
Market Cap: $638.376M info